Trial Profile
A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Jul 2023
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms CORRECT
- Sponsors Bayer; Bayer HealthCare
- 06 Jun 2023 Results of Matching-adjusted indirect treatment comparison assessing the efficacy and safety of sotorasib with standard of care trifluridine/tipiracil and regorafenib as monotherapy treatments using data from NCT01607957, NCT01103323 and NCT03600883 trials, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 02 Jul 2022 Results of a network analysis of data pooled from 3 global (ReDOS, CORRECT, RECOURSE) and 3 Asian (TERRA, Yoshino 2012, and CONCUR) studies assessed the impact of regorafenib dose optimization on clinical outcomes compared to best supportive care and TAS-102 in the treatment of relapsed/refractory metastatic colorectal cancer presented at the 24th World Congress on Gastrointestinal Cancer
- 22 Jan 2022 Results of a pooled analysis (NCT02122913, NCT02637687, NCT02576431, NCT01607957 and NCT01103323 )comparing the expected life-years and quality-adjusted life-years for metastatic CRC patients eligible to receive larotrectinib, regorafenib or trifluridine/tipiracil.presented at the 2022 Gastrointestinal Cancers Symposium